Cytox, a leading developer of assays for risk assessment and
prediction of dementia, announced the timing of a presentation
discussing the development of a novel proprietary blood-based assay for
the assessment of risk of cognitive decline.
The talk, entitled "The evaluation of mTOR pathway dysregulation as a
novel blood-based phenotypic risk biomarker for the assessment of
Alzheimer's Disease and dementia" will be given on Thursday 17
July, between 08.30 and 10.00am, during the AAIC Symposia and
Featured Research Sessions at the Bella Centre, A/S Convention Center,
Copenhagen, by Professor Harald Hampel of Université Pierre et
Marie Curie (Sorbonne), Paris, France.
More information about the event and Professor Hampel's presentation
can be found on the AAIC Conference website at http://bit.ly/1sGQyPh
The presentation refers to two on-going clinical studies in which blood
samples are being collected from patients in Europe and in the United
States. One study will examine mTOR dysregulation in well-characterized
patients who have been diagnosed with probable Alzheimer's Disease,
Fronto-temporal Lobe Dementia (FTLD) or Dementia with Lewy bodies (DLB)
against cognitively normal control groups.
A second study will evaluate the performance of the assay platform in
patients with mild cognitive impairment (MCI) assessing the relationship
between the assay output (mTOR dysregulation) and the presence or
absence of amyloid plaques in the brain, a pathological hallmark of
Alzheimer's Disease, using Positron Emission Tomography (PET) imaging.
About Cytox Limited
Cytox Limited is a UK company researching into the role of mTOR pathway
dysfunction and the associated development of prognostic tests for
cognitive decline and risk of developing AD or other dementias. Cytox
has exclusive rights to build on the discoveries made by the company's
scientific founder, Dr. Zsuzsanna Nagy of cell cycle-related biomarkers
associated with the risk of developing dementia. The company is
developing her work and assessing its significance in trials and will be
looking to work with pharmaceutical partners to develop our
understanding of the technology and its role in drug development.
For more about the mTOR pathway and its potential role in early
identification of risk of Dementia and Alzheimer's disease, follow this
[ Back To NFVZone's Homepage ]